Update shared on01 Aug 2025
Fair value Decreased 46%Despite an increase in forecasted revenue growth, Pulmonx's significant decline in Future P/E suggests reduced investor confidence in earnings quality or sustainability, prompting a notable drop in the consensus analyst price target from $12.50 to $9.25.
What's in the News
- Pulmonx Corporation lowered full-year 2025 revenue guidance to $90–92 million, down from prior expectations of $96–98 million.
Valuation Changes
Summary of Valuation Changes for Pulmonx
- The Consensus Analyst Price Target has significantly fallen from $12.50 to $9.25.
- The Future P/E for Pulmonx has significantly fallen from 34.48x to 24.06x.
- The Consensus Revenue Growth forecasts for Pulmonx has risen from 20.0% per annum to 21.8% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.